ASP Isotopes Inc. (NASDAQ:ASPI – Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $7.97, but opened at $7.37. ASP Isotopes shares last traded at $7.0650, with a volume of 1,369,192 shares trading hands.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on ASPI shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $11.00 price objective on shares of ASP Isotopes in a research report on Tuesday, April 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $13.00.
Read Our Latest Stock Report on ASP Isotopes
ASP Isotopes Price Performance
ASP Isotopes (NASDAQ:ASPI – Get Free Report) last announced its quarterly earnings results on Wednesday, May 20th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06. ASP Isotopes had a negative net margin of 644.40% and a negative return on equity of 112.46%. The firm had revenue of $8.36 million for the quarter, compared to the consensus estimate of $3.68 million.
Insider Activity
In other news, CEO Paul Elliot Mann sold 83,759 shares of the stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $7.76, for a total value of $649,969.84. Following the sale, the chief executive officer directly owned 9,579,845 shares of the company’s stock, valued at approximately $74,339,597.20. This represents a 0.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Heather Kiessling sold 23,124 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $5.48, for a total transaction of $126,719.52. Following the completion of the sale, the chief financial officer directly owned 709,376 shares in the company, valued at approximately $3,887,380.48. The trade was a 3.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 224,783 shares of company stock valued at $1,648,923. Corporate insiders own 14.40% of the company’s stock.
Institutional Investors Weigh In On ASP Isotopes
A number of institutional investors and hedge funds have recently modified their holdings of ASPI. Encompass Capital Advisors LLC purchased a new stake in shares of ASP Isotopes in the first quarter worth about $30,551,000. Alyeska Investment Group L.P. increased its position in shares of ASP Isotopes by 73.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company’s stock worth $26,191,000 after purchasing an additional 2,072,851 shares during the last quarter. UBS Group AG increased its position in shares of ASP Isotopes by 150.3% in the fourth quarter. UBS Group AG now owns 2,406,457 shares of the company’s stock worth $12,875,000 after purchasing an additional 1,445,165 shares during the last quarter. Marshall Wace LLP increased its position in shares of ASP Isotopes by 3,669.1% in the third quarter. Marshall Wace LLP now owns 1,279,121 shares of the company’s stock worth $12,305,000 after purchasing an additional 1,245,184 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of ASP Isotopes by 37.9% in the third quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock worth $43,451,000 after purchasing an additional 1,241,024 shares during the last quarter. 16.80% of the stock is owned by hedge funds and other institutional investors.
ASP Isotopes Company Profile
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
Featured Stories
- Five stocks we like better than ASP Isotopes
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
- Broadcom’s Whiplash: Shares Tank After Pre-Earnings Surge
- Five Below Down 12% Post Earnings—Is the Selloff Overdone?
Receive News & Ratings for ASP Isotopes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASP Isotopes and related companies with MarketBeat.com's FREE daily email newsletter.
